GSK 3878858A
Alternative Names: GSK-3878858ALatest Information Update: 07 Feb 2025
At a glance
- Originator GlaxoSmithKline
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Skin and soft tissue infections
Most Recent Events
- 12 Mar 2024 GlaxoSmithKline completes a phase I trial in Skin and soft tissue infections (In prevention) (IM) (NCT04420221)
- 03 Feb 2023 Discontinued - Phase-II for Skin and soft tissue infections (Prevention) in USA (IM) (GlaxoSmithKline pipeline, February 2023)
- 30 Jun 2021 Phase-II clinical trials in Skin and soft tissue infections (Prevention) in USA (IM) (GlaxoSmithKline pipeline, June 2021)